Roivant Sciences Ltd
NASDAQ:ROIV
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
9.08
23.81
|
| Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
This alert will be permanently deleted.
Operating Margin
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Operating Margin shows how much profit a company makes from its regular business activities after covering operating costs. It helps measure how efficiently the company turns sales into profit.
Peer Comparison
| Country | Company | Market Cap |
Operating Margin |
||
|---|---|---|---|---|---|
| BM |
|
Roivant Sciences Ltd
NASDAQ:ROIV
|
16B USD |
Loading...
|
|
| US |
|
Eli Lilly and Co
NYSE:LLY
|
982.2B USD |
Loading...
|
|
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP |
Loading...
|
|
| US |
|
Johnson & Johnson
NYSE:JNJ
|
526.1B USD |
Loading...
|
|
| CH |
|
Roche Holding AG
SIX:ROG
|
276.2B CHF |
Loading...
|
|
| UK |
|
AstraZeneca PLC
LSE:AZN
|
215.4B GBP |
Loading...
|
|
| CH |
|
Novartis AG
SIX:NOVN
|
221.7B CHF |
Loading...
|
|
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.7B USD |
Loading...
|
|
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.7T DKK |
Loading...
|
|
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD |
Loading...
|
|
| US |
|
Pfizer Inc
NYSE:PFE
|
145.8B USD |
Loading...
|
Market Distribution
| Min | -73 643.6% |
| 30th Percentile | 2.6% |
| Median | 6.8% |
| 70th Percentile | 19.1% |
| Max | 68.5% |
Other Profitability Ratios
Roivant Sciences Ltd
Glance View
Roivant Sciences Ltd. emerged as an intriguing figure in the pharmaceutical landscape, founded by the charismatic and driven Vivek Ramaswamy. The company operates like a strategic mosaic in the biotech industry, acquiring and developing promising drug candidates through a distinctive model that emphasizes speed and efficiency. At the heart of Roivant's strategy are its "Vants"—subsidiary companies that each focus on developing a specific type of therapeutic drug. This compartmentalized approach allows Roivant to cultivate multiple drug development streams simultaneously, mitigating risk while maximizing potential returns. By acquiring undervalued or overlooked drugs from larger pharmaceutical companies and advancing them through clinical trials, Roivant creates a robust pipeline of therapies ready to address unmet medical needs. Roivant generates revenue through the monetization of these therapies, either by bringing them to market directly or through strategic partnerships and licensing deals with larger pharmaceutical companies. By advancing drugs to critical points in clinical development, the company enhances their value significantly before either monetizing through commercialization or strategic exits like IPOs or partnerships. This business model creates a strong position in the drug development value chain, allowing Roivant to capture returns on its investments with focused precision. Additionally, Roivant brings an innovative twist to biotech investing by leveraging data analytics and technology to guide its decisions, aiming to streamline the traditionally costly and time-consuming drug development process. Beyond the financials, this approach paints Roivant as not just a player in biopharma but as an architect reshaping how medical innovations can reach patients more efficiently.
See Also
Operating Margin is calculated by dividing the Operating Income by the Revenue.
The current Operating Margin for Roivant Sciences Ltd is -5 659.4%, which is below its 3-year median of -2 484.2%.
Over the last 3 years, Roivant Sciences Ltd’s Operating Margin has decreased from -2 134.3% to -5 659.4%. During this period, it reached a low of -5 659.4% on Oct 30, 2025 and a high of -871.9% on Dec 31, 2023.